BullFrog AI Holdings, a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, provided an update on its collaboration with Eleison Pharmaceuticals, a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers.
To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to handle the scale and complexity of Eleison’s historical clinical data. Originally created to convert more than 10,000 pages of clinical trial PDFs into an OMOP-standardized dataset for Eleison, the module proved so effective that it has since become a standalone commercial offering of BullFrog AI called bfPREP™.
“Our bfPREP™ module turns legacy and siloed clinical trial data into a strategic asset,” said Vin Singh, CEO of BullFrog AI. “In the case of Eleison, we were dealing with a vast amount of complex clinical documentation, the kind of data that typically slows down or derails analytics efforts. With our purpose-built, proprietary technology, we were able to ingest, clean, and standardize that data at scale, transforming it into a foundation for actionable insights. It’s a clear demonstration of how our enterprise-grade platforms can handle the volume, variability, and nuance of real-world clinical datasets, positioning BullFrog AI as a highly capable and trusted partner to the pharmaceutical industry.”
Also Read: SOPHiA GENETICS and Jessa Ziekenhuis Announce Precision Oncology Partnership
Scalable AI-Driven Value Creation
Following ingestion, BullFrog AI applied feature engineering and AI-enhanced curation to extend the dataset, categorizing diseases, medications, lesion descriptors, and normalizing free text into structured fields. Using a layered approach, where automation handles repeatable tasks and human reviewers ensure accuracy, the Company was able to rapidly scale data preparation while maintaining the integrity and nuance required for clinical decision-making.
The structured dataset was then deployed into bfLEAP®, BullFrog AI’s core analytics engine, to identify data-driven patient subgroups ahead of randomization. These insights may inform both trial design and market positioning, as they illuminate patient segments most likely to benefit from Eleison’s therapies.
“This initiative demonstrates how bfPREP™ and bfLEAP® can improve patient targeting and create meaningful insights to accelerate trial efficiency for pharmaceutical partners. We view this as a strong proof point for the broader application of our platforms across the drug development landscape,” added Mr. Singh.
“We’ve been impressed by BullFrog’s rigor and responsiveness and are extremely pleased with the collaboration to date,” said Matt Cromie, MS, VP Clinical Development at Eleison. “We look forward to continuing our efforts together.”
SOURCE: GlobeNewswire